Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
Therapeutics announced that the US FDA accepted the NDA and granted Priority Review for rusfertide. An investigational, first-in-class hepcidin mimetic peptide, rusfertide is intended for the treatment of adults with polycythemia vera/PV. The FDA established a Prescription Drug User Fee Act target action date within Q3 2026. This milestone follows previous Breakthrough Therapy, Orphan Drug, and Fast Track designations granted to the therapeutic. The regulatory submission is primarily supported by results from the Phase 3 VERIFY study and long-term data from the Phase 2 REVIVE and THRIVE studies. In the VERIFY trial, rusfertide combined with standard of care more than doubled clinical response rates compared to standard care alone. Patients experienced improvements in hematocrit control, a reduction in the need for phlebotomy, and improved patient-reported outcomes regarding fatigue and symptom burden. Takeda Pharmaceutical Company Limited (NYSE:TAK) and Protagonist entered a world
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026) [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (TAK) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".MarketBeat
- Major biopharmaceutical company to lay off nearly 250 workers in MA [Yahoo! Finance]Yahoo! Finance
- DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Massachusetts' largest biopharma employer to lay off 237 in Cambridge [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 4/6/26 - Form 3
- 4/6/26 - Form 3
- 4/6/26 - Form 3
- TAK's page on the SEC website